NSC 66811MDM2 inhibitor CAS# 6964-62-1 |
2D Structure
- P 22077
Catalog No.:BCC3616
CAS No.:1247819-59-5
- SJB2-043
Catalog No.:BCC1952
CAS No.:63388-44-3
- Vialinin A
Catalog No.:BCC2367
CAS No.:858134-23-3
- P005091
Catalog No.:BCC1287
CAS No.:882257-11-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 6964-62-1 | SDF | Download SDF |
PubChem ID | 248986 | Appearance | Powder |
Formula | C23H20N2O | M.Wt | 340.42 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO | ||
Chemical Name | 7-[anilino(phenyl)methyl]-2-methylquinolin-8-ol | ||
SMILES | CC1=NC2=C(C=C1)C=CC(=C2O)C(C3=CC=CC=C3)NC4=CC=CC=C4 | ||
Standard InChIKey | WEENRMPCSWFMTE-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C23H20N2O/c1-16-12-13-18-14-15-20(23(26)22(18)24-16)21(17-8-4-2-5-9-17)25-19-10-6-3-7-11-19/h2-15,21,25-26H,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent MDM2 inhibitor (Ki = 120 nM) which disrupts MDM2-p53 interaction and activates p53 function. Induces p21, p53 and MDM2 accumulation in human colon cancer cells in vitro. |
NSC 66811 Dilution Calculator
NSC 66811 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.9375 mL | 14.6877 mL | 29.3755 mL | 58.751 mL | 73.4387 mL |
5 mM | 0.5875 mL | 2.9375 mL | 5.8751 mL | 11.7502 mL | 14.6877 mL |
10 mM | 0.2938 mL | 1.4688 mL | 2.9375 mL | 5.8751 mL | 7.3439 mL |
50 mM | 0.0588 mL | 0.2938 mL | 0.5875 mL | 1.175 mL | 1.4688 mL |
100 mM | 0.0294 mL | 0.1469 mL | 0.2938 mL | 0.5875 mL | 0.7344 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
NSC 66811 is a small-molecule inhibitor of the murine double minute 2 (MDM2) p53 interaction with Ki value of 120nM [1].
The N-terminus of p53 and a deep hydrophobic cleft in MDM2 form a short helix between p53 and MDM2. NSC 66811 binds the active site of this cleft. NSC 66811 has a high binding affinity with Ki of 120nM and is 56 times more potent than the natural p53 peptide. The stereoisomers of NSC 66811 mimic the three key residues of p53 (Phe19, Trp26, and Leu26), mediating the interaction with MDM2. NSC 66811 is reported to induce the accumulation of p53, MDM2, and p21cip1/waf proteins in the HCT-116 human colon cancer cell line with wild-type p53. However, NSC 66811 has no effect on the levels for p53, MDM2, and p21cip1/waf protein in the isogenic HCT-116 p53 /cell line [1].
References:
[1] Lu Y, Nikolovska-Coleska Z, Fang X, Gao W, Shangary S, Qiu S, Qin D, Wang S. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy. J Med Chem. 2006 Jun 29;49(13):3759-62.
- Pd-C-II
Catalog No.:BCN4599
CAS No.:
- H-D-Met-OMe.HCl
Catalog No.:BCC2998
CAS No.:69630-60-0
- H-D-Asp(OMe)-OMe.HCl
Catalog No.:BCC2897
CAS No.:69630-50-8
- Chamaejasmine
Catalog No.:BCN3132
CAS No.:69618-96-8
- CRT0044876
Catalog No.:BCC5109
CAS No.:6960-45-8
- 4-Hydroxybenzylamine
Catalog No.:BCN1805
CAS No.:696-60-6
- Tupichilignan A
Catalog No.:BCN4257
CAS No.:69586-96-5
- Octadecyl caffeate
Catalog No.:BCN6609
CAS No.:69573-60-0
- Thymopentin
Catalog No.:BCN8347
CAS No.:69558-55-0
- Boc-D-His(Tos)-OH
Catalog No.:BCC3405
CAS No.:69541-68-0
- 2-Methyl-4-isobutyrylphloroglucinol
Catalog No.:BCN7176
CAS No.:69480-03-1
- Parvifuran
Catalog No.:BCN7780
CAS No.:69470-93-5
- 5'-Methoxynobiletin
Catalog No.:BCN8031
CAS No.:6965-36-2
- Hesperetin 5-O-glucoside
Catalog No.:BCN3934
CAS No.:69651-80-5
- Trichloro-1,4-dimethoxybenzene
Catalog No.:BCN3494
CAS No.:69653-71-0
- Didanosine
Catalog No.:BCC3763
CAS No.:69655-05-6
- Tanshinone IIA-sulfonic sodium
Catalog No.:BCN2541
CAS No.:69659-80-9
- 6-Aminoindazole
Catalog No.:BCC8762
CAS No.:6967-12-0
- (Z-Cys-OH)2
Catalog No.:BCC2917
CAS No.:6968-11-2
- Mepiroxol
Catalog No.:BCC3810
CAS No.:6968-72-5
- Oleaside A
Catalog No.:BCN6772
CAS No.:69686-84-6
- 2,5-Dimethylchroman-4-one
Catalog No.:BCN7200
CAS No.:69687-87-2
- VIP (6-28) (human, rat, porcine, bovine)
Catalog No.:BCC5838
CAS No.:69698-54-0
- DCB
Catalog No.:BCC7212
CAS No.:6971-97-7
VEGF alleviates ALS-CSF induced cytoplasmic accumulations of TDP-43 and FUS/TLS in NSC-34 cells.[Pubmed:28163215]
J Chem Neuroanat. 2017 Apr;81:48-52.
Cytoplasmic mislocalisation and aggregation of TDP-43 and FUS/TLS proteins in spinal motor neurons contribute to the pathogenesis of the highly fatal disorder amyotrophic lateral sclerosis (ALS). We investigated the neuroprotective effect of VEGF on expression of these proteins in the motor neuronal cell line NSC-34 modelled to reminisce sporadic form of ALS. We studied the expression of TDP-43 and FUS/TLS proteins after exposure to ALS-CSF and following VEGF supplementation by quantitative confocal microscopy and electron microscopy. ALS-CSF caused cytoplasmic overexpression of both the proteins and stress-granule formation in the cells. These alterations were alleviated by VEGF supplementation. The related ultrastructural changes like nuclear membrane dysmorphism and p-bodies associated changes were also reversed. However the protein expression did not completely translocate to the nucleus, as some cells continued to show to cytoplasmic mislocalisation. Thus, the present findings indicate that VEGF alleviates TDP43 and FUS pathology by complimenting its role in controlling apoptosis and reversing choline acetyl transferase expression. Hence, VEGF appears to target multiple pathogenic processes in the neurodegenerative cascade of ALS.
Important modifications by sugammadex, a modified gamma-cyclodextrin, of ion currents in differentiated NSC-34 neuronal cells.[Pubmed:28049438]
BMC Neurosci. 2017 Jan 3;18(1):6.
BACKGROUND: Sugammadex (SGX) is a modified gamma-cyclodextrin used for reversal of steroidal neuromuscular blocking agents during general anesthesia. Despite its application in clinical use, whether SGX treatment exerts any effects on membrane ion currents in neurons remains largely unclear. In this study, effects of SGX treatment on ion currents, particularly on delayed-rectifier K(+) current [I K(DR)], were extensively investigated in differentiated NSC-34 neuronal cells. RESULTS: After cells were exposed to SGX (30 muM), there was a reduction in the amplitude of I K(DR) followed by an apparent slowing in current activation in response to membrane depolarization. The challenge of cells with SGX produced a depolarized shift by 15 mV in the activation curve of I K(DR) accompanied by increased gating charge of this current. However, the inactivation curve of I K(DR) remained unchanged following SGX treatment, as compared with that in untreated cells. According to a minimal reaction scheme, the lengthening of activation time constant of I K(DR) caused by cell treatment with different SGX concentrations was quantitatively estimated with a dissociation constant of 17.5 muM, a value that is clinically achievable. Accumulative slowing in I K(DR) activation elicited by repetitive stimuli was enhanced in SGX-treated cells. SGX treatment did not alter the amplitude of voltage-gated Na(+) currents. In SGX-treated cells, dexamethasone (30 muM), a synthetic glucocorticoid, produced little or no effect on L-type Ca(2+) currents, although it effectively suppressed the amplitude of this current in untreated cells. CONCLUSIONS: The treatment of SGX may influence the amplitude and gating of I K(DR) and its actions could potentially contribute to functional activities of motor neurons if similar results were found in vivo.
Adult NSC diversity and plasticity: the role of the niche.[Pubmed:27978480]
Curr Opin Neurobiol. 2017 Feb;42:68-74.
Adult somatic stem cells are generally defined as cells with the ability to differentiate into multiple different lineages and to self-renew during long periods of time. These features were long presumed to be represented in one single tissue-specific stem cell. Recent development of single-cell technologies reveals the existence of diversity in fate and activation state of somatic stem cells within the blood, skin and intestinal compartments [1] but also in the adult brain. Here we review how recent advances have expanded our view of neural stem cells (NSCs) as a diverse pool of cells and how the specialized microenvironment in which they reside acts to maintain this diversity. In addition, we discuss the plasticity of the system in the injured brain.
c-Jun Amino-Terminal Kinase is Involved in Valproic Acid-Mediated Neuronal Differentiation of Mouse Embryonic NSCs and Neurite Outgrowth of NSC-Derived Neurons.[Pubmed:28321599]
Neurochem Res. 2017 Apr;42(4):1254-1266.
Valproic acid (VPA), an anticonvulsant and mood-stabilizing drug, can induce neuronal differentiation, promote neurite extension and exert a neuroprotective effect in central nervous system (CNS) injuries; however, comparatively little is known regarding its action on mouse embryonic neural stem cells (NSCs) and the underlying molecular mechanism. Recent studies suggested that c-Jun N-terminal kinase (JNK) is required for neurite outgrowth and neuronal differentiation during neuronal development. In the present study, we cultured mouse embryonic NSCs and treated the cells with 1 mM VPA for up to 7 days. The results indicate that VPA promotes the neuronal differentiation of mouse embryonic NSCs and neurite outgrowth of NSC-derived neurons; moreover, VPA induces the phosphorylation of c-Jun by JNK. In contrast, the specific JNK inhibitor SP600125 decreased the VPA-stimulated increase in neuronal differentiation of mouse embryonic NSCs and neurite outgrowth of NSC-derived neurons. Taken together, these results suggest that VPA promotes neuronal differentiation of mouse embryonic NSCs and neurite outgrowth of NSC-derived neurons. Moreover, JNK activation is involved in the effects of VPA stimulation.
Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.[Pubmed:16789731]
J Med Chem. 2006 Jun 29;49(13):3759-62.
An integrated, virtual database screening strategy has led to 7-[anilino(phenyl)methyl]-2-methyl-8-quinolinol (4, NSC 66811) as a novel inhibitor of the murine double minute 2 (MDM2)-p53 interaction. This quinolinol binds to MDM2 with a Ki of 120 nM and activates p53 in cancer cells with a mechanism of action consistent with targeting the MDM2-p53 interaction. It mimics three p53 residues critical in the binding to MDM2 and represents a promising new class of non-peptide inhibitors of the MDM2-p53 interaction.